- Conference Abstract
- Open access
- Published:
P.39 The Role of Advanced Glycation End Products in Vascular Ageing. Which Parameter is the Most Suitable as Biomarker?
Artery Research volume 26, page S61 (2020)
Abstract
Background
Advanced glycation end products (AGEs) are involved into several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of vessel wall (arterial stiffness). Circulating soluble receptor for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor [1,2]. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding natural course of arterial stiffening.
Methods
In a prospective cohort study, we longitudinally followed 536 general-population-based subjects (subsample of Czech post-MONICA study). Aortic pulse wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd.), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxylmethyl lysine (circulating AGEs) were assessed at follow-up visit by ELISA, while skin AGEs were measured using autofluorescence-based device AGE Reader.
Results
Using multiple regressions, we found significant association between ∆PWV/year as dependent variable and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest association to ∆PWV/year were found for ratio of these two factors (skin AGEs/sRAGE) [coeff = 0.0747 (SE 0.0189), p < 0.0001]. In categorized manner, subjects with skin AGEs/sRAGE ratio ≥3.3 showed about two-fold higher risk having PWV/year ≥0.2 m/sec [adjusted odds ratio was 2.09 (95% CI: 1.35–3.22), p = 0.001]. In contrast neither circulating AGEs nor circulating AGEs/sRAGE showed any significant relation to PWV/ year.
Conclusions
Skin AGEs/sRAGE ratio seems to be more sensitive biomarker of vascular ageing than these single factors themselves or circulation status of AGEs [3].
References
Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol 2014;23:11–16.
Geroldi D, Falcone C, Emanuele E, D’Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725–9.
Mayer O, Gelžinský J, Seidlerová J, Mateřánková M, Mareš Š, Svobodová V, et al. The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker? J Hum Hypertens 2020.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Mayer, O., Gelžinský, J., Seidlerová, J. et al. P.39 The Role of Advanced Glycation End Products in Vascular Ageing. Which Parameter is the Most Suitable as Biomarker?. Artery Res 26 (Suppl 1), S61 (2020). https://doiorg.publicaciones.saludcastillayleon.es/10.2991/artres.k.201209.051
Published:
Issue Date:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.2991/artres.k.201209.051